Commercial Services and Supplies
Company Overview of Newcastle University
Newcastle University is an educational institution.
Newcastle, NE1 7RU
Founded in 1963
Key Executives for Newcastle University
Director of the Institute of Cell and Molecular Biosciences
Compensation as of Fiscal Year 2014.
Newcastle University Key Developments
Prosensa Holding N.V. and Newcastle University Receive FP7 Research Grant from European Commission
Nov 25 13
Prosensa Holding N.V. and Newcastle University have announced the award of a second Framework Programme 7 (FP7) research grant from the European Commission. This new FP7 research grant totals approximately EUR 6 million to support the development of imaging biomarkers for Duchenne muscular dystrophy (DMD). The project - Developing imaging technologies for therapeutic interventions in rare diseases - will be known as BIOIMAGE-NMD and is expected to run three and a half years. The pan-European BIOIMAGE-NMD consortium includes leading expert centers in DMD already working together in another recently awarded FP7 project called SCOPE-DMD as well as additional partners with strong expertise and experience in bio-imaging. The SCOPE-DMD project, which was initiated earlier this year, was also awarded EUR 6 million as announced previously. This FP7 project aims to evaluate Prosensa's exon 45 skipping drug candidate, PRO045, in an innovatively designed clinical proof-of-concept study in boys with DMD. The academic partners in the BIOIMAGE-NMD project are Newcastle University as the coordinating partner, and University College London (UCL) in the United Kingdom; the Institute of Myology in France; the Leiden University Medical Centre in The Netherlands; Universita Cattolica del Sacro Cuore (UCSC) in Italy; and the Katholieke Universiteit Leuven (KULeuven) in Belgium. These academic centers are working alongside a number of industrial partners including Prosensa, SCITO, based in France, and Consultants for Research in Imaging and Spectroscopy (CRIS). BIOIMAGE-NMD will be conducting MRI scans in a number of exon skipping drug candidates, including PRO053, which is currently in Phase I/II clinical development. The compound induces exon 53 skipping in the dystrophin gene and could be suitable for up to 8% of all DMD patients.
BBC Launches User Experience Research Partnership with University of Bath, University Of Dundee, University College London, Newcastle University, Nottingham University and Swansea University
Jul 18 13
The BBC on July 18, 2013 announced the BBC User Experience Research Partnership, a long-term collaboration project between BBC Research and Development (BBC R&D) and leading universities in the fields of User Experience and Human Computer Interaction research. The academic partners will be The University of Bath, The University of Dundee, University College London, Newcastle University, The University of Nottingham and Swansea University, which have all committed to support the initiative for at least four years. Through large-scale pilots and prototypes, the partnership will explore the potential of new forms of content and interaction in a multi-platform world, alongside new ways of producing media that will help make content more accessible to all audiences. The research outcomes will be shared with the industry to encourage wider audience-focused innovation, help define open standards and support the creative industries in producing engaging content in the future. The technical scope of the partnership covers: The User Experience of an IP Broadcasting System: developing user-centred services across multiple platforms to help advance public service broadcasting in the digital age; Designing for New Interaction: Moving beyond gesture and voice to develop new ways of controlling and displaying digital content for more natural and engaging interfaces; Sustainable Approaches to User Capability: Allowing the industry to meet the changing needs of older users, young children and people with disabilities in accessing digital media; New Production Interface Technologies: Using novel interface and interaction technologies in new ways to give production teams the most creative and effective ways to craft new forms of content. The initiative builds on BBC R&D's strong history of industry and academic collaboration, which includes the Audio Research Partnership and a strategic partnership with UCL, by establishing another centre of excellence for research into areas of strategic importance to the BBC and the wider industry.
Autifony Therapeutics Collaborates with University of Manchester and Newcastle University to Develop First-in-Class Treatment for Schizophrenia
Jul 2 13
Imperial Innovations Group plc announced that its portfolio company, Autifony Therapeutics is collaborating with research groups at the University of Manchester and Newcastle University to develop a first-in-class treatment for schizophrenia. The £2.75 million research collaboration is part-funded by the Biomedical Catalyst which awarded a £1.9 million grant to Autifony and the two Universities. The funding will enable selection and progression of a compound from a group of potential candidates through to application to conduct clinical trials. Schizophrenia is a serious psychiatric illness that has a high unmet need and imposes a huge social and economic burden. Research into schizophrenia has seen diminishing investment in recent years, with existing schizophrenia treatments demonstrating poor efficacy and considerable side effects for many patients. Autifony recently initiated a Phase I clinical study, expected to complete in the first quarter of 2014, as part of its lead programme to develop first-in-class drugs for hearing loss and tinnitus.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|